Elsevier
September 2023 marks the 12th anniversary of World Alzheimer’s Month, our international campaign to raise awareness and challenge stigma. In 2022, over 111 countries took part in advocacy, fundraising and awareness raising events for World Alzheimer’s Month, with many working to raise general awareness and call for further support for those most affected in their communities. The month of activities shows a truly global, regional, national and local level response to promote dementia awareness and what we can do to help support those living with the disease, now and in the future. Only through increased awareness will more people seek out information, advice and support. With the potential to improve diagnosis rates, encourage further research, including around areas as such as risk reduction, and handle the growing demand of access to treatment and care, World Alzheimer’s Month has never been more important.
The focus of this year’s World Alzheimer’s Month campaign, ‘Never too early, never too late’, centres on risk factors and risk reduction, aiming to emphasise their crucial role in delaying and potentially preventing the onset of dementia. This also importantly includes ongoing risk reduction for those who have already been diagnosed. With the number of people living with dementia set to almost triple by 2050, it has never been more important to recognise the risk factors associated with dementia and take proactive steps towards risk reduction. In addition to challenging the stigma around dementia and promoting a better understanding of the disease, we can work together to reduce the impact of dementia on individuals, families and global society as a whole.
Elsevier
This podcast discusses the relevance of lipid oxidation in brain activity, how work in redox proteomics helps us to understand the role of specific proteins in the development of Alzheimer's pathology, why metabolic disorders have such a major risk factor for the development of dementia. how down syndrome is a model of Alzheimer's and Dr. Butterfield's thoughts on future antioxidant strategies in the prevention and treatment of Alzheimer's & new therapeutic approaches. Plus advice for young people pursuing science and medicine as a career.
Elsevier,
Brain Responses to Auditory Mismatch and Novelty Detection, First Edition, 2023, pp 271-314
This chapter advances the UN SDG goals 3 and 17 understanding whether decreasing network connectivity in aging is independent of changes across cognitive networks or is accelerated by mild cognitive impairment and AD.
Elsevier,
Oxidative Stress: Its Mechanisms and Impacts on Human Health and Disease Onset, 2023, Pages 291-297
This chapter advances the UN SDG goal 3 and 17 by discussing how Alzheimer's disease risk factors, as well as the mechanism for onset and progression, are related to elevated oxidative stress.
Elsevier,
The Lancet Regional Health - Europe, Volume 29, June 2023
This Viewpoint supports Sustainable Development Goal 3 by estimating the potential financial cost of lecanemab, a drug for early Alzheimer's disease, if it were to be approved in Europe at the same price as in the USA. The authors suggest that pricing would be unsustainable and that new payment models will be needed to address affordability and inequalities in access.
Elsevier,
The Lancet Regional Health - Europe, Volume 26, March 2023
This Health Policy article supports Sustainable Development Goal 3 by presenting recommendations for implementation of second-generation memory clinics to assess potentially modifiable risk factors for brain pathology and to reduce risk.
Elsevier,
Free Radical Biology and Medicine, Volume 204, 1 August 2023
In vivo triple transgenic AD mouse model brains and retinas showed hypoxic vessels expressing hypoxyprobe and HIF-1α. In in vitro OGD-treated endothelial cells, HIF-1α upregulated NADPH oxidase (NOX) (i.e., Nox2, Nox4). NLRP1 protein was promoted by OGD, and such effect was blocked by downregulation of Nox4 and HIF-1α. Hypoxic endothelial cells of AD brains and retinas markedly expressed NLRP1, ASC, caspase-1, and interleukin-1β (IL-1β). Chronic hypoxia in microvascular endothelial cells leads to HIF-1α-NLRP1 circuit in AD.
Elsevier,
Redox Biology, Volume 62, June 2023
SCFA contribute to the glutamate-glutamine shuttle by acting on glutamine synthetase. Long-term SCFA diet alleviates cognitive and spatial memory defeat in APP/PS1 mice. Long-term SCFA diet reduces Aβ deposition and abnormal phosphorylation of tau. SCFA promote astrocyte-neuron metabolic coupling to reduce oxidative damage.
Elsevier,
Free Radical Biology and Medicine, Volume 193, 20 November 2022
DNA glycosylase Neil3 leads to sex-specific differences in AD. Neil3 increases plaque deposition in female APP/PS1 mice. Neil3 promotes hippocampal neurogenesis and working memory in male APP/PS1 mice. Neil3-dependent DNA damage accumulation does not correlate with AD pathogenesis.
Elsevier, Free Radical Biology and Medicine, Volume 183, April 2022
Genistein is a phytoestrogen that, due to its structural similarity with estrogen, can both mimic and antagonize estrogen effects. Early analysis proved that at high concentrations, genistein inhibits breast cancer cell proliferation, thereby suggesting an anticancer activity. Since then, many discoveries have identified the genistein mechanism of action, including cell cycle arrest, apoptosis induction, as well as angiogenesis, and metastasis inhibition.
Elsevier,
Redox Biology, Volume 48, December 2021
MiRNA mouse models are emerging tools to study the protective and/or deleterious effects of miRNAs in human diseases. In the current study, miR-455-3p TG and KO models were successfully generated by using pronuclear injection of miR-455-3p transgene to mouse embryo and CRISPER/Cas9 knockout techniques.
Elsevier,
Free Radical Biology and Medicine, Volume 134, April 2019
More than 30 sterols/oxysterols/sterol-acids analysed in human CSF. 7α,25-Dihydroxy-3-oxocholest-4-en-26-oate reduced in AD patient-group. 7α,25-Dihydroxy-3-oxocholest-4-en-26-oate – an intermediate in bile acid synthesis. Bile acid synthesis linked to AD.
Elsevier,
SLAS Discovery, Volume 28, June 2023
In this study, a novel reporter substrate named C8CF3-coumarin was synthesized and then characterized, an assay protocol was developed to identify small molecular activators of PLCγ enzymes, and a proof-of-principle high throughput screen was conducted using PLCγ2 and the LOPAC1280 library. These studies showed that C8CF3-coumarin could indeed monitor PLCγ enzyme activity and identify potential small molecule activators from a screen. The identification of such small molecule PLCγ2 activators would be of great utility to the Alzheimer's disease research community by serving as both chemical probes to study the modulation of PLCγ2 and as potential therapeutic agents.
Elsevier,
Comparative Biochemistry and Physiology Part - C: Toxicology and Pharmacology, Volume 271, September 2023
OKA is a potent neurotoxin and has a profound effect on cognitive dysfunction in Zebrafish. 4D and 10D OKA treated zebrafish show significant changes in gene expressions related to neuroinflammation. OKA exposed zebrafish display a substantial number of proteins that are involved in contributing to AD pathology. OKA-induced AD in zebrafish model can be used as a screening tool to explore further underlying possible mechanisms.
Elsevier,
Mitochondrion, Volume 65, July 2022
The way how the emergence of mitochondria research field improved our knowledge on the hmajor metabolic pathways. How mitochondria 3-D architecture fits with different cellular and physiological functions. Putative interlink between mitochondrial dysfunction and neurodegeneration – the cases of AD and PD. Strategies to develop a mitochondria-targeted therapy for neurodegenerative diseases.
Elsevier,
The Lancet Healthy Longevity, Volume 3, November 2022
This Personal View makes a contribution to Sustainable Development Goal 3 by summarising the advances is early detection, drug development, and trial methodology which the authors argue should be used in brain health clinics to develop new therapies for Alzheimer's disease.
Elsevier,
Geriatric Nursing, Volume 53, 1 September 2023
This article underscores the need to screen early for balance issues and fall risk in patients with Alzheimer's, as these patients are more prone to falls. The end goal is to promote earlier screening so as to better improve their quality of life.
Elsevier,
Engineering Applications of Artificial Intelligence, Volume 123, August 2023
Using brain tissue from donors with Alzheimer's disease, Anderson et al. identify new links between gene regulation and disease. These regulators could represent future clinical targets or disease markers for Alzheimer's diagnosis and treatment.
Elsevier,
Measurement: Sensors, Volume 27, June 2023
The authors explore automatic and early detection methods for Alzheimer’s disease (AD) using deep learning techniques in order to improve the speed and accessibility of current testing methods. They propose a deep transfer learning model as a new approach for accurately detecting categories of Alzheimer's disease. The research serves SDG 3's aim in highlighing and seeking better treatment for AD, an increasingly serious global public health issue.
Elsevier,
Heliyon, Volume 9, May 2023
This study assessed the central auditory processing (CAP) function and its electroencephalogram (EEG) in patients with mild cognitive impairment (MCI) and the early stage of Alzheimer's disease (AD) so as to provide a basis for early recognition and intervention of AD.
Elsevier, Cell Genomics, Volume 3, 8 March 2023
Cell type-specific transcriptional differences between brain tissues from donors with Alzheimer's disease (AD) and unaffected controls have been well documented, but few studies have rigorously interrogated the regulatory mechanisms responsible for these alterations. We performed single nucleus multiomics (snRNA-seq plus snATAC-seq) on 105,332 nuclei isolated from cortical tissues from 7 AD and 8 unaffected donors to identify candidate cis-regulatory elements (CREs) involved in AD-associated transcriptional changes.
Elsevier,
Heliyon, Volume 9, March 2023
This paper investigates mitochondrial dysfunctions at an early event in the progression of neuropathological processes. It found that that mtDNA mutation is a major contributor to the metabolic pathology of most neurological disorders, causing changes in genes important for physiological homeostasis.
Elsevier,
The Lancet Healthy Longevity, Volume 4, January 2023
This Article supports Sustainable Development Goal 3 by examining whether psychological intervention for anxiety disorders is associated with a lower incidence of dementia. The results suggest that improvement in anxiety from these therapies was associated with reduced incidence of future dementia.
Elsevier,
Mutation Research - Genetic Toxicology and Environmental Mutagenesis, Volume 883-884, 1 November 2022
This manuscript provides an overview of studies exploring cognitive dysfunction related to DNA damage due to biological ageing process, cancer treatment, adverse environmental or occupational exposures, and prenatal genotoxic exposure.
Elsevier, Cell Genomics, Volume 2, 14 September 2022
Most disease-gene association methods do not account for gene-gene interactions, even though these play a crucial role in complex, polygenic diseases like Alzheimer's disease (AD). To discover new genes whose interactions may contribute to pathology, we introduce GeneEMBED. This approach compares the functional perturbations induced in gene interaction network neighborhoods by coding variants from disease versus healthy subjects. In two independent AD cohorts of 5,169 exomes and 969 genomes, GeneEMBED identified novel candidates.
Elsevier,
Mutation Research - Genetic Toxicology and Environmental Mutagenesis, Volume 874-875, 1 February 2022
This review focus on the mechanisms by which oxidative stress, mitochondrial dysfunction, ER stress, and inflammation are involved in the pathophysiology of T2D, highlighting the importance of the antioxidant response and DNA repair mechanisms counteracting the development of the disease.
Elsevier, Frontiers in Neuroendocrinology, Volume 60, January 2021
Women represent ⅔ of the cases of Alzheimer's disease (AD). Current research has focused on differential risks to explain higher rates of AD in women. However, factors that reduce risk for AD, like cognitive/brain reserve, are less well explored. We asked: what is known about sex and gender differences in how reserve mitigates risk for AD?
Elsevier,
Journal of Trace Elements in Medicine and Biology, Volume 79, September 2023
The role of estrogen and ferroptosis in Alzheimer's disease is known. Ginseng has estrogen-like effects as well as a regulatory role in Alzheimer's disease and iron metabolism and this paper discusses for the frist time the link between ginseng, ferroptosis, and Alzheimer's disease.
Elsevier,
Nitric Oxide - Biology and Chemistry, Volume 134-135, 1 May 2023
Nitric Oxide can act as both protecting and aggravating factor in Alzheimer's Disease. Nitric oxide can be considered as a neurotoxic factor in Alzheimer's Disease. Nitric Oxide induces neuro plasticity, neuroprotection, neurogenesis, long-term potentiation, and myelination. Drugs based on Nitric Oxide have shown promising results in Alzheimer's Disease. Nitric Oxide can via sundry ways ameliorate memory formation.
Elsevier,
Immunity, Volume 55, 13 December 2022
Chen and Holtzman review the emerging roles of both innate and adaptive immunity, their alterations, their interplay, and their contributions to the development and progression of Alzheimer’s disease. They proposed that targeting dysregulated innate and adaptive immune responses in both brain parenchyma and border structures could lead to important therapeutics for preventing and treating the disease.
Elsevier,
Mitochondrion, Volume 59, July 2021
Mitophagy, a selective type of autophagy, eliminates selectively damaged/weakened mitochondria. Impaired mitophagy emerges in early AD progression. Compromised mitophagy contributes to mitochondrial dysfunction and abnormal energy metabolism in AD. Targeting mitophagy could be a promising therapeutic avenue for the prevention and treatment of AD.
Elsevier,
The Lancet Healthy Longevity, Volume 4, August 2023
This Article supports Sustainable Development Goal 3 by showing that although there was an increase in prescribing of antipsychotics to people with dementia during the COVID-19 pandemic, this increase was not responsible for the large increase in all-cause and stroke mortality in this population.
Elsevier,
The Lancet Healthy Longevity, Volume 4, August 2023
This Article supports Sustainable Development Goal 3 by showing that although there was an increase in prescribing of antipsychotics to people with dementia during the COVID-19 pandemic, this increase was not responsible for the large increase in all-cause and stroke mortality in this population.
Elsevier,
The Lancet Healthy Longevity, Volume 4, July 2023
This Article supports Sustainable Development Goal 3 by assessing the impact of physical activity and sleep on 10-year cognitive decline in older people. They showed that the cognitive benefits associated with increased activity were not enough to ameliorate decline associated with short sleep.
Elsevier,
The Lancet Healthy Longevity, Volume 4, January 2023
This Article supports Sustainable Development Goal 3 by examining whether psychological intervention for anxiety disorders is associated with a lower incidence of dementia. The results suggest that improvement in anxiety from these therapies was associated with reduced incidence of future dementia.
Elsevier,
The Lancet Regional Health - Europe, Volume 29, June 2023
This Viewpoint supports Sustainable Development Goal 3 by estimating the potential financial cost of lecanemab, a drug for early Alzheimer's disease, if it were to be approved in Europe at the same price as in the USA. The authors suggest that pricing would be unsustainable and that new payment models will be needed to address affordability and inequalities in access.
Elsevier,
The Lancet Regional Health - Europe, Volume 26, March 2023
This Health Policy article supports Sustainable Development Goal 3 by presenting recommendations for implementation of second-generation memory clinics to assess potentially modifiable risk factors for brain pathology and to reduce risk.
Elsevier,
eBioMedicine, Volume 94, August 2023
This Article supports Sustainable Development Goal 3 by identifying an independent relationship between anxiety and subsequent cognitive progression in older people without dementia; these findings suggest that treating anxiety and targeting mitochondrial dysfunction may be effective in preventing dementia.
Elsevier,
eBioMedicine, Volume 84, October 2022
This Review supports Sustainable Development Goal 3 by summarising human studies on the association between brain and visceral white adipose tissue, and defines their interaction and underlying mechanisms on the basis of animal and cell studies.
Elsevier,
The Lancet Regional Health - Western Pacific, Volume 33, April 2023
This Article supports Sustainable Development Goal 3 by estimating the incidence and risk factors for vascular cognitive symptoms among first-ever stroke survivors in China, and shows an association of post-stroke cognitive impairment with age, education, and region (western China had higher rates of post-stroke cognitive impairment relative to other regions).
Elsevier,
eBioMedicine, Volume 92, June 2023
This Article supports Sustainable Development Goal 3 by highlighting differential effects of sleep disturbances on resting-state neural activity in patients on the Alzheimer's disease spectrum relative to healthy adults, suggesting a key role of sleep disturbances in the neurophysiological changes seen in Alzheimer's disease, with implications for basic research and clinical intervention.
Elsevier,
eBioMedicine, Volume 94, August 2023
This Article supports Sustainable Development Goal 3 by advancing our understanding of the possible role of active immunotherapy against amyloid-β in individuals with mild Alzheimer's disease; the findings of this phase 2a study support the continued clinical development of UB-311 as an active immunotherapy for Alzheimer's disease.
Elsevier,
eBioMedicine, Volume 92, June 2023
This Article supports Sustainable Development Goal 3 by describing a cohort characterization model for Alzheimer’s Disease built on medications and diagnoses data that are widely available in a structured format in electronic health records (EHRs), showing that standard machine learning applied to sequences of EHR data can produce scalable computational characterization of Alzheimer’s disease cohorts.
Elsevier,
Lancet Regional Health - Americas, Volume 20, April 2023
This Viewpoint supports Sustainable Development Goal 3 by discussing the effects of the FDA's approval of aducanumab, a treatment for early-stage Alzheimer's disease, despite its limited clinical benefit, as well as the decision of the Centers for Medicare and Medicaid Services to restrict coverage to individuals enrolled in clinical trials. The authors note that these decisions have led to a confusing landscape for patients with Alzheimer's disease.
Elsevier,
Lancet Regional Health - Americas, Volume 17, January 2023
This Article supports Sustainable Development Goal 3 by developing a methodology for discriminating between and classifying Alzheimer's disease and frontotemporal dementia according to demographic, clinical, and cognitive data, across centres in Latin America. The approach provided high accuracy with the combination of classical statistical and machine learning procedures.
Elsevier, eClinicalMedicine, Volume 51, September 2022
This Article supports Sustainable Development Goal 3 by developing projections of the economic burden of Alzheimer's disease and related dementias, up to 2050. The study predicts that the burden will be $16.9 trillion in 2050, compared with $2.8 trillion in 2019. The authors note that more funding is needed for research into prevention and treatment of Alzheimer's disease.
Elsevier,
The Lancet. Public health, Volume 8, 1 September 2023
This Article supports Sustainable Development Goal 3 by calculating the proportion of dementia in Australia attributable to 11 potentially modifiable risk factors. They found that 38% of dementia was attributable to these risk factors (increasing to 41% when a 12th risk factor, traumatic brain injury, was added). The authors note that these findings could help to guide culturally specific dementia risk reduction programmes.
Elsevier,
The Lancet Public Health, Volume 8, May 2023
This Article supports Sustainable Development Goal 3 by showing a positive association between hearing loss without hearing aid use and dementia in adults aged 40-69 years in the UK. The authors analysed all-cause dementia, as well as specific types including Alzheimer's disease. Hearing loss was associated with increased risk of dementia, and using hearing aids was associated with a similar risk of dementia to no hearing loss, suggesting that hearing aid use in people with hearing loss could reduce dementia risk.
Elsevier,
eClinicalMedicine, Volume 60, June 2023
This Article supports Sustainable Development Goal 3 by estimating the proportion of dementia attributable to hypertension, finding an overall global population attributable fraction of 15.8%. Results were also broken down by region and age. The authors note that the estimates from this study could help to inform public health policy at global and national levels.
The Lancet Healthy Longevity, Volume 3, Issue 7, July 2022, Pages e501-e512
This Personal View supports Sustainable Development Goal 3 by summarising the limitations of existing research into the role of nutritional factors in dementia, and propose recommendations to guide future trial developments.
Elsevier,
The Lancet Regional Health - Southeast Asia, Available online 24 August 2023, 100257
This Article supports Sustainable Development Goal 3 by estimating the prevalence of dementia in people aged 60 years and older in Bangladesh, finding an overall prevalence of 8%, and identifying positive associations between dementia prevalence and female sex, advanced age, and lower education levels.
